SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant attention as investors speculate on its AI-driven infrastructure and potential for long-term utility growth within the Base ecosystem. The community remains focused on accumulation and holding, viewing recent market dips as entry points for a project they believe is heavily undervalued relative to its sector peers.

Microchip Technology, Inc. engages in the provision of semiconductor products. It operates through the Semiconductor Products and Technology Licensing segments. The Semiconductor Products segment is involved in designing, developing, manufacturing, and marketing microcontrollers, development tools and analog, interface, mixed signal, connectivity devices, and timing products. The Technology Licensing segment offers license fees and royalties associated with technology licenses for the use of SuperFlash embedded flash and Smartbits one-time programmable technologies. The company was founded on February 14, 1989 and is headquartered in Chandler, AZ.

Microchip Technology, Inc.

Microchip Technology is trending as the community debates its recovery potential and valuation amid a challenging semiconductor cycle. Investors are closely monitoring its operational rebound following a recent cyberattack while weighing its long-term positioning in industrial, automotive, and data center markets.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing high volatility as investors navigate aggressive swings driven by a mix of geopolitical tensions, central bank policy concerns, and sector-specific earnings. Community sentiment is deeply polarized, with active debates centered on whether the current semiconductor rally is a sustainable AI-driven shift or a speculative bubble vulnerable to a sharp correction.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

Community sentiment for XRP remains heavily influenced by the anticipated passage of the CLARITY Act, which investors believe will provide regulatory certainty and facilitate broader institutional integration for the token. Discussions are currently polarized between bulls who are actively accumulating on dips in expectation of a major price rally and skeptics who remain cautious due to historical price volatility and market structure concerns.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors digest its latest earnings report, which featured raised full-year guidance and strong AI-driven demand, despite short-term concerns regarding export controls and semiconductor market volatility. Community members are actively debating the stock's long-term dominance in lithography against broader macro risks, with many traders closely monitoring the impact of AI infrastructure spending on equipment demand.

Direxion Shares ETF Trust - Direxion Daily Gold Miners Index Bull 2X ETF

Direxion Daily Gold Miners Index Bull 2X Shares

NUGT is experiencing intense volatility as traders debate whether the stock is primed for a parabolic breakout fueled by macro economic uncertainty and central bank gold accumulation or if it is currently overbought and facing a significant correction. Community discussion is heavily divided between long-term bulls positioning for a potential commodity supercycle and traders capitalizing on daily swings and technical indicators signaling a possible reversal.

Leidos Holdings, Inc. engages in providing services and solutions in the defense, intelligence, civil and health markets. It operates through the following three segments: Defense Solutions, Civil, and Health. The Defense Solutions segment provides services, solutions, and products focusing on digital modernization, mission systems and integration, command, control, computers, communications, intelligence, surveillance and reconnaissance technologies and services, maritime solutions, transformative software, analytics, intelligence analysis, mission support and logistics services, weapons systems and space systems and solutions. The Civil segment focuses on modernizing infrastructure, systems, and security. The Health segment offers solutions to federal and commercial customers that are responsible for the health and wellbeing of people worldwide including service members and veterans. The company was founded by John Robert Beyster on February 3, 1969 and is headquartered in Reston, VA.

Leidos Holdings Inc

Leidos Holdings, Inc. (LDOS) is drawing investor attention as it secures major defense and logistics contracts, including a notable multibillion-dollar airport security equipment sustainment deal. While the stock has faced volatility amid market concerns regarding government spending efficiency, the community remains divided, with bulls highlighting its robust backlog and role in critical defense modernization, while bears express caution over sector-wide downward trends.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as investors weigh the stock's recent volatility against its aggressive expansion into crypto trading and AI-integrated wealth management tools. The community remains divided, with many traders discussing the firm's system reliability and restrictions, while others view the pullback as a buying opportunity given the company's strong long-term client asset growth.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest the commercial launch progress of Yartemlea, supported by the recent assignment of a permanent reimbursement J-code that simplifies billing and hospital adoption. Community discussions center on the company's long-term potential, with bullish sentiment driven by the drug's first-in-class status for TA-TMA and anticipation of upcoming European regulatory catalysts.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies is gaining momentum as investors eye the company's rare earth magnet production capacity and its strategic positioning within the domestic critical minerals supply chain. Community discussion centers on the stock's low-float structure and potential for volatility, with many users tracking its resilience compared to the broader mining sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aclarion, Inc. (ACON) Reports Q1 Loss, Misses Revenue Estimates

Aclarion (ACON) delivered earnings and revenue surprises of +13.55% and -29.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sonida Senior Living (SNDA) Reports Q1 Loss, Tops Revenue Estimates

Sonida Senior Living (SNDA) delivered earnings and revenue surprises of -43.11% and +24.60%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

Natera (NTRA) delivered earnings and revenue surprises of -5.26% and +13.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Teladoc (TDOC) Reports Q1 Loss, Beats Revenue Estimates

Teladoc (TDOC) delivered earnings and revenue surprises of -13.82% and +0.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aclarion Authorized To Repurchase Up To $2.5 Mln Of Shares

<ul class="summary-bullets"><li>CEO Brent Ness outlined a 2026 execution plan focused on reimbursement, evidence, and adoption.</li><li>Monetization is underway through UK coverage, cash-pay usage, and paid trials.</li><li>Scanner expansion is seen as a key lever to broaden market reach.</li></ul>Aclarion Inc.’s stock has plunged nearly 98% over the past year, putting the spotlight back on the artificial intelligence-driven medical imaging company almost four years after it went public. Despite the steep decline, Aclarion is now attempting to follow a path similar to HeartFlow,&nbsp;an AI medtech firm focused on cardiac imaging, that went public just months ago with significantly higher quarterly revenue and greater investor visibility.In an exclusive interview with Stocktwits, CEO Brent Ness said Aclarion is already generating revenue. In this interview, edited for clarity, Ness explained how the Broomfield, Colorado-based company is working to regain investor confidence after a prolonged period of decline.<h2 class="st-heading-2">HeartFlow's Playbook Offers Guidance For Aclarion</h2>Ness compared Aclarion’s strategy to that of advanced imaging companies such as HeartFlow, noting that the “raw material data” comes from imaging centers, is processed in the cloud, and is delivered to physicians in a clinically meaningful report.Under this structure, imaging centers generate raw data that is processed through Aclarion’s platform and translated into clinically meaningful reports for physicians. Ness said customer acquisition and technology development are expensive, but delivering a cloud-to-customer scan has a “nice margin profile.”He said investors should look at HeartFlow “as a proxy business” when thinking about Aclarion’s economic profile. HeartFlow’s platform uses AI to generate personalized three-dimensional models of the heart, helping make coronary artery disease more screenable, diagnosable and manageable.Aclarion went public in April 2022, while HeartFlow made its market debut in August 2025. Over the past six months, HTFL has shed about 1.3% to keep its market capitalization at $2.45 billion, while ACON has slumped by nearly 60%, with its valuation hovering just above $3 million.&nbsp;HeartFlow’s quarterly revenue has increased from $26.8 million in the first quarter of 2024 to $46.3 million in the third quarter of 2025, while adjusted losses narrowed slightly, from $15.6 million to $14.8 million over the same period.&nbsp;Aclarion had approximately $21 million in cash at the beginning of January, giving the company a funding runway through 2028.<img src="https://news.stocktwits-cdn.com/Heart_Flow_Revenue_and_EBITDA_jpg_728fe48fd3.webp" alt="HeartFlow_Revenue_and_EBITDA.jpg"><h2 class="st-heading-2">A Big Market With Room To Scale</h2>Ness said Aclarion’s opportunity spans a large patient population, noting that approximately 266 million people worldwide live with chronic low back pain. He said the company’s addressable market spans multiple layers of care, including spinal fusion surgeries, non-fusion procedures, and pain management, collectively increasing the potential number of scans over time.According to a MarketsandMarkets&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketsandmarkets.com/PressReleases/ai-in-medical-imaging.asp">report</a>, the global AI in medical imaging market is projected to reach $4.54 billion by 2029, up from $1.65 billion in 2024, reflecting a 22.4% compound annual growth rate. The report said growth is driven by the rising adoption of AI software that improves diagnostic accuracy, streamlines workflows, and helps providers manage increasing imaging volumes.On potential near-term catalysts, Ness said the company is focused on reimbursement progress and expanding access. “We’re currently in the market only with Siemens scanners. If you see Philips scanners, Canon scanners, GE scanners coming on board, then that will increase the penetrable market size significantly.”<h2 class="st-heading-2">Early Monetization Gains Ground</h2>Ness said Aclarion is generating revenue from multiple sources, including reimbursed Nociscan scans in the UK, cash-pay usage, and paid clinical trials that compensate the company for use of its technology.He said the UK, particularly London, has played a key role because insurance coverage reduces financial friction for physicians and patients, thereby supporting higher utilization and growth in scan volume.Ness said clinical trials are also generating revenue, with some studies paying Aclarion to use Nociscan to evaluate spine treatments and biologics. He said this allows evidence generation to function as an income stream rather than a pure cost center, helping offset operating expenses and reducing reliance on capital markets during key development milestones.<h2 class="st-heading-2">Aclarion Clarity Trial And Reimbursement Pathway</h2>Ness said Aclarion’s national randomized Clarity trial is central to its U.S. reimbursement strategy. The trial is designed to enroll up to 300 patients, with physicians blinded or unblinded to Nociscan results. It will measure outcomes at 3, 6, and 12 months post-surgery, with additional follow-up at 24 months.Since it is a post-market study and not an FDA approval trial, he said the study includes an early-stop design, meaning enrollment could be halted if outcome separation becomes statistically significant, potentially accelerating discussions with insurers.Ness said that a 2025 paper by an independent PhD healthcare economist found Nociscan reduced costs by about $1,700 per patient, strengthening the case for payer adoption. He added that nearly $2.2 billion is spent each year in the U.S. on fusion revision surgeries, and said reducing that figure is a significant opportunity for payers.<h2 class="st-heading-2">ACON vs HTFL: Which Stock Is Getting Higher Retail Interest?</h2>On Stocktwits, Aclarion’s retail sentiment was ‘bearish’ amid ‘extremely low’ message volume, a sharp shift from ‘extremely bullish’ sentiment a year ago. HeartFlow’s sentiment was also ‘bearish’ with ‘normal’ message volume, down from ‘neutral’ levels last year.<figure class="image"><img src="https://news.stocktwits-cdn.com/acon_ss_png_3176ea0056.webp" alt="acon ss.png" width="967" height="140"><figcaption>ACON sentiment and message volume as of February 4 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/htfl_ss_png_d3f3abe807.webp" alt="htfl ss.png" width="966" height="141"><figcaption>HTFL sentiment and message volume as of February 4 | Source: Stocktwits</figcaption></figure>One user said they were accumulating Aclarion shares and watching closely for a pickup in trading volume, adding that “a fast double is very possible.”<stembedurl>https://stocktwits.com/KuruHabesha/message/643772716</stembedurl>Another Stocktwits user said HeartFlow’s momentum would likely persist only if the company continues to show consistency quarter to quarter, adding that operational execution needs to tighten meaningfully and that sustained improvement could help validate the long-term thesis.<stembedurl>https://stocktwits.com/MarketSignalMatrix/message/640221754</stembedurl>Up until the end of January, HTFL notched a more than 15% jump in watchers on Stocktwits over a three-month period, while ACON saw a merely 2.7% rise in followers, indicating stronger growth in retail investor interest for Heartflow. Message volume for HTFL doubled over the same period, while ACON witnessed a 25% drop.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aclarion logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

EXCLUSIVE: Aclarion CEO Looks To Bigger AI MedTech’s Playbook To Reverse Fortunes 

CEO Brent Ness noted a broad global market, with approximately 266 million people affected by chronic low back pain.

Aclarion CEO Bets On Bigger AI MedTech’s Playbook To Revive Sagging Stock

Equity

<ul class="summary-bullets"><li>A Supreme Court ruling on tariffs and the U.S. jobs report were scheduled for Friday.</li><li>Housing, biotech and aviation stocks saw notable moves during regular and extended trading.</li><li>Markets tracked developments related to trade policy, mortgage bonds and economic data.</li></ul>U.S. stock futures were mixed late Thursday as investors positioned cautiously ahead of a key U.S. jobs report and weighed a series of policy signals out of Washington that could influence trade, rates, and housing markets.As of 9.05 P.M. ET, Nasdaq 100 futures were down 0.2%, while S&amp;P 500 futures&nbsp;were down by 0.1%. Dow futures were up 0.6%.On Stocktwits, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> was ‘neutral’, while sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> was ‘bullish’ and sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> was ‘extremely bearish’, all amid ‘high’ message volume.<h2 class="st-heading-2">Market Drivers</h2>Markets reacted to two potential catalysts heading into Friday: a possible ruling from the U.S. Supreme Court on the legality of tariffs imposed under President Donald Trump and his latest comments on mortgage markets.In the prior session, the Dow Jones Industrial Average rose 0.6%, while the S&amp;P 500 climbed 0.01% and the Nasdaq Composite slid 0.4%.Trump said in a social media post on Thursday that he is instructing his representatives to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-instructs-to-buy-200-billion-dollars-in-mortgage-bonds/cmUbZfwR45k">buy $200 billion in mortgage bonds</a>, arguing that the move would help lower mortgage rates and monthly payments. He added that Fannie Mae and Freddie Mac have about $200 billion in cash, framing the directive as a way to make homeownership more affordable.The comments came a day after Trump said he would&nbsp;seek to ban large institutional investors from buying single-family homes, citing rising inflation and high housing costs as a growing barrier for younger Americans.<h2 class="st-heading-2">Peter Schiff Pushes Back On Mortgage Bond Buying</h2>Economist Peter Schiff&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/PeterSchiff/status/2009416426738626693">said on X</a> that lower home prices, rather than additional credit, were the only solution to the housing affordability crisis. He argued that directing more government-backed credit into the mortgage market would allow buyers to stretch further and overpay for homes, worsening the problem.Schiff also said&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/PeterSchiff/status/2009391071760142624">in a separate post</a> that if the $200 billion were sourced from government-sponsored entities, it could reduce availability for U.S. Treasuries. While such purchases might temporarily push mortgage rates lower, he warned they could also lead to higher Treasury yields and increased inflation pressures.<h2 class="st-heading-2">Trending Stocks To Watch</h2>Opendoor Technologies: Shares jumped more than 12% after hours after rising about 5% in regular trading, as comments on mortgage-related policy lifted housing-linked stocks.Rocket Companies: The stock gained 7% in extended trading after slipping 0.2% during the regular session, also moving on mortgage and rate-related news.Aclarion: Shares fell about 13% after hours after surging more than 42% in regular trading, following an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acon-stock-pops-pre-market-today-what-s-driving-the-move/cmUbeT3R4Pp">update on business progress</a>, rising demand for its Nociscan platform, and its financial position heading into 2026.flyExclusive: The stock more than doubled during regular trading, up over 130%, after the company announced an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/flyx-stock-surges-130-percent-whats-the-spacex-connection/cmUbfvrR45T">authorized dealership agreement with Starlink</a> to install high-speed connectivity across its fleet.Oscar Health: Shares rose nearly 7% after hours after gaining about 3% in regular trading, as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-surges-over-after-hours-as-house-backs-obamacare-subsidies/cmUcxWmR45N">investors reacted to a House vote backing</a> ACA subsidy extensions, despite a disclosed insider share sale.Enliven Therapeutics: The stock added about 1% after hours after soaring roughly 50% during the session, following positive early data from its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-elvn-stock-shoot-up-60-percent-today/cmUbQNvR45E">Phase 1b Enable trial</a> for ELVN-001 in chronic myeloid leukemia.<h2 class="st-heading-2">Broader Markets</h2>In broader markets, oil prices rebounded after two straight days of declines, settling at a two-week high. Brent crude rose $2.03, or 3.4%, to $61.99 a barrel, while U.S. West Texas Intermediate gained $1.77, or 3.2%, to $57.76.&nbsp;The yield on the benchmark 10-year U.S. Treasury was last around 4.18%. Asian equities were mixed, with shares opening higher in Japan and Australia, while South Korea lagged.Among the catalysts for the day are housing starts and building permits figures, updated University of Michigan consumer sentiment readings, and remarks from Minneapolis Fed President Neel Kashkari and Richmond Fed President Tom Barkin.For updates and corrections, email newsroom[at]stocktwits[dot]com.

People walk past the New York Stock Exchange (NYSE) on August 22, 2025, in New York City. (Photo by Spencer Platt/Getty Images)

S&P 500, Nasdaq Futures Waver Ahead Of Supreme Court Ruling On Trump Tariffs: Why OPEN, ACON, FLYX, OSCR Are Trending After-Hours

Attention also centered on Trump’s comments on proposed mortgage bond purchases.

Healthcare Stocks To Keep An Eye On - January 8th

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Aclarion, and Hims & Hers Health are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. As it...

<ul class="summary-bullets"><li>In 2025, Aclarion added nine imaging sites and more than 20 new physician users.</li><li>The company reported a 69% increase in annual scan volume, capped by triple-digit growth in the fourth quarter.</li><li>Looking to 2026, the company expects to speed up CLARITY trial enrollment, and roll out a new version of its software to improve workflow integration.&nbsp;</li></ul>Aclarion, Inc. (ACON) stock shot up over 45% on Thursday’s premarket after the company shared an overview of its latest business progress and financial performance as it heads into 2026 and continues to develop its Nociscan platform.The healthcare technology company focuses on helping physicians pinpoint the source of chronic lower back pain using biomarkers and advanced analytics embedded in its Nociscan platform.<h2 class="st-heading-2">Momentum Gained In 2025</h2>Demand for Nociscan continued to accelerate through 2025, with scan volumes rising sharply across the U.S., the U.K., and Europe as new imaging centers and physician users came onboard.In 2025, Aclarion added nine imaging sites and more than 20 new physician users. The company said these steps supported a 69% increase in annual scan volume, capped by triple-digit growth in the fourth quarter.On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/ACON">Aclarion stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_08_073305_png_e7268d46e3.webp" alt="ACON’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Jan. 8, 2026 | Source: Stocktwits" width="932" height="104"><figcaption>ACON’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Jan. 8, 2026 | Source: Stocktwits</figcaption></figure>Aclarion launched its CLARITY trial in 2025, activating seven sites to evaluate real-world performance. The company also published data indicating Nociscan could lower per-patient costs and improve surgical success rates.<h2 class="st-heading-2">Plans For 2026</h2>Looking to 2026, the company expects to speed up CLARITY trial enrollment, expand compatibility with additional MRI manufacturers, and roll out a new version of its software to improve workflow integration.&nbsp;<blockquote>“We are pleased with the progress Aclarion has made in strengthening our financial position, expanding clinical traction, and advancing Nociscan toward broader adoption.”- Brent Ness, CEO, Aclarion</blockquote>As of the end of 2025, Aclarion reported $12 million in cash and no outstanding debt. Based on current spending levels, the company said it has sufficient resources to operate into the first half of 2027.ACON stock has declined by over 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/exclusive-richtech-robotics-coo-bets-on-single-use-robots-as-dex-targets-real-world-labor-gaps/cmUb5USR4Pj">Exclusive: Richtech Robotics COO Bets On Single-Use Robots As Dex Targets Real-World Labor Gaps</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Aclarion logo is seen displayed on a smartphone screen.

ACON Stock Pops 45% Pre-Market Today: What’s Driving The Move?

The company said demand for Nociscan continued to accelerate through 2025, with scan volumes rising sharply across the U.S., the U.K., and Europe as new imaging centers and physician users came onboard.

AMN Healthcare Services (AMN) Tops Q2 Earnings and Revenue Estimates

AMN Healthcare (AMN) delivered earnings and revenue surprises of +76.47% and +0.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

ACON
Aclarion Inc

Feed

News

Sentiment

Fundamentals

Info

Historical Earnings

Latest ACON News

ACONAclarion Inc